24/7 Market News Snapshot 25 June, 2025 – Adial Pharmaceuticals, Inc (NASDAQ:ADIL)

June 25, 2025

DENVER, Colo., 25 June, 2025 (www.247marketnews.com) – (NASDAQ:ADIL) are discussed in this article.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) experienced a notable increase in its stock price, opening at $0.258 and currently trading at $0.272, reflecting a substantial gain of 18.62%. This rise follows a previous close of $0.229, indicating a positive shift in market sentiment, likely correlated with recent strategic developments within the company. Current trading volume stands at 12.20 million shares, suggesting heightened investor engagement and interest, which may indicate a sustained upward momentum. Investors are encouraged to monitor potential resistance levels as this trend develops.

Concurrently, Adial has announced the execution of significant drug production agreements with premier contract development and manufacturing organizations Cambrex and Thermo Fisher Scientific. These partnerships are crucial for advancing Adial’s lead investigational product, AD04, which targets Alcohol Use Disorder (AUD). Cambrex will support the production of the drug substance, leveraging their expertise in Ondansetron active pharmaceutical ingredient (API) manufacturing. In contrast, Thermo Fisher will manage the manufacturing services necessary for upcoming clinical trials and the submission of a New Drug Application (NDA) to regulatory bodies.

Cary Claiborne, the President and CEO of Adial, emphasized the importance of these collaborations, stating that they represent a critical advancement towards launching Phase 3 registrational trials for AD04. The ONWARD™ pivotal trial has already demonstrated promising results in reducing heavy drinking in specific patient populations without major safety concerns. By securing these strategic partnerships, Adial is well-positioned to meet clinical and commercial demands while enhancing its operational capabilities in the dynamic regulatory landscape. This progress reflects Adial’s commitment to developing innovative treatments for AUD and related disorders, marking an essential milestone in its ongoing mission to improve addiction therapies.

Related news for (ADIL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.